VANCOUVER, British Columbia, April 13, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class...
Alignment with the FDA across proposed study parameters of RESTORE, a 16-week registrational study evaluating NVG-291 in chronic tetraplegia. Primary endpoint will be the change from baseline in GRASSP...
Completed End-of-Phase 2 meeting with the FDA; Company expects to provide a regulatory update in early 2Q 2026 and remains on track to initiate a Phase 3 study in chronic tetraplegia in mid-2026. ...
The Company’s common shares will continue to trade on Nasdaq under the symbol “NGEN” No action is required; all shareholders, including Canadian shareholders, will continue to maintain full trading...
VANCOUVER, British Columbia, March 04, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing...
Toronto, Ontario--(Newsfile Corp. - February 23, 2026) - The following is a list of Upcoming Meeting Dates announced this week for Reporting Issuers in Canada. The data is supplied by Issuing Companies...
VANCOUVER, British Columbia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing...
VANCOUVER, British Columbia, Feb. 12, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing...
Adam Rogers, MD, President and Chief Executive Officer of NervGen to present and discuss clinical data from the Phase 1b/2a CONNECT SCI Study demonstrating durable improvement in function, independence,...
VANCOUVER, British Columbia, Feb. 09, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing...